A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Leahy, Michael F (Chief Investigator (CI))
  • Ross, David Morrall (Chief Investigator (CI))
  • Prasad, Ritam (Chief Investigator (CI))
  • Kennedy, Nola (Project Manager)
  • Choi, Philip (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date5/02/20 → 31/12/25

Keywords

  • Clinical Haematology
  • Myelofibrosis
  • Clinical trial

Clinical Trial Phase

  • Phase III (a & b)